AstraZeneca to present new insights from the THALES Phase III trial on the prevention of the composite of recurrent stroke or death at ESO-WSO 2020

7th to 9th November 2020

We are at the virtual European Stroke Organisation and the World Stroke Organization Conference (ESO-WSO) 2020 to share detailed results from the THALES Phase III trial for the first time at a medical congress alongside a prespecified exploratory analysis investigating the use of Brilinta (ticagrelor) in preventing disabling stroke.

Further, we will present two real-world evidence (RWE) studies on the burden of illness of patients with a stroke or transient ischaemic attack (TIA), with disease characteristics similar to those enrolled in the THALES trial. Both RWE studies will help us generate insights on the medical need for early secondary prevention in clinical practice.

AstraZeneca’s presence at ESO-WSO 2020 marks another step forward in our ambition to help reduce atherosclerotic risk and reduce the risk of subsequent stroke – building off our established heritage in cardiovascular disease. 





Our Abstracts



Brilinta (ticagrelor) 

For the first time, detailed results of the THALES Phase III trial will be presented at a medical congress alongside data from a prespecified exploratory analysis that evaluated the benefit of Brilinta in reducing subsequent disabling stroke or death in patients who had an acute ischaemic stroke or TIA. 

 



Real-world evidence

Two retrospective analyses of stroke registry data from the US and Korea will generate RWE on the burden of illness of patients with a minor ischaemic stroke or high-risk TIA in clinical practice.  












Learn more about our work in CVRM:

Our aim is to protect the lives of 50 million people in 2020 from the often-devastating consequences of heart failure, cardiovascular, metabolic and renal diseases. Learn more about how we are:




Abstract list

All ESO-WSO 2020 Virtual Conference abstracts are available via their Scientific Programme for registered participants. The presentations will be accessible for viewing from the first day of the conference until three months after it.

Brilinta

·       Ticagrelor and Aspirin Versus Aspirin Alone in Acute Ischemic Stroke and Tia: Results of the Thales Trial - Johnston SC (Plenary: 7 November, 02:31 PM - 02:46 PM CET)

Real-World Evidence

·       Burden of Illness for United States Medicare Beneficiaries with Non-cardioembolic Minor Ischemic Stroke or High Risk Transient Ischemic Attack: A Retrospective Analysis - Shah S (ePoster Presentation: 7 November, 06:10 - 06:15 PM CET)

·       One-Year Risk Of Subsequent Events In Patients With Minor Acute Ischemic Stroke Or High-Risk Transient Ischemic Attack; Risk Of Disability And Subsequent Stroke Or Death By Aetiological Subtype In Korean Patients With Minor Acute Ischaemic Stroke Or High-Risk Transient Ischaemic Attack - Bae HJ (ePoster Viewing) 



References:

1. Hankey GJ. Secondary stroke prevention. The Lancet Neurology 2014; 13(2):178–94.

2. Coull AJ et al. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: Implications for public education and organisation of services. BMJ 2004; 328(7435):326

3. National Health Service. Treatment: Stroke; 15 Aug 2019 [cited 26 Oct 2020]. Available from: URL: https://www.nhs.uk/conditions/stroke/treatment/.

4. Johnson CO et al. Global, regional, and national burden of stroke, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 2019; 18(5):439–58.

5. Hankey GJ. Secondary stroke prevention. The Lancet Neurology 2014; 13(2):178–94.

6. World Health Organization. WHO World Heart Day: Scale up prevention of heart attack and stroke: World Health Organization; 2019 [cited 29 Oct 2020]. Available from: URL: https://www.who.int/cardiovascular_diseases/world-heart-day/en/.




Veeva ID: Z4-28640
Date of Preparation: November 2020